CRISPR Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, everyone. My name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. I would like to welcome the CRISPR Therapeutics team. We have Sam Kulkarni, the CEO, and Naimish Patel, the CMO. Thanks so much for joining us today. We are going to do fireside chat format, so maybe for those who are new to the story, if you can give a one-minute intro to CRISPR.
Yeah. Thank you, Maury, for having us. It is always fun to be at this conference. We have had an incredible year in 2026 for CRISPR and are poised for even better pipeline and portfolio progression in 2027. What we have is a business that you can categorize into three parts. We have CASGEVY, which is our commercial product, which is getting a lot of momentum, and we will talk more about that. This is in partnership with Vertex, and we believe this could be a multi-billion dollar opportunity. We have our later-stage clinical products, and these are namely CTX310, which is for ANGPTL3 and reduction of triglycerides. We have zugo-cel, which is an allogeneic CAR T, and we have CTX611, which is an siRNA targeted towards Factor XI. Those could all be potentially in late-stage trials within a year or so.
That is actually incredible progress for three programs that could be best in class, and also first in class. Then we have a number of other things in the pipeline which are also very exciting. We have alpha-1 antitrypsin, where we are in the clinic. We have CTX340, which is targeted towards refractory hypertension, and a number of other earlier programs like type 1 diabetes, which will go into the clinic, not too distant future, in vivo CAR T, in vivo HSC editing, et cetera. So, all in all, a very rich pipeline, and we are quite excited about each of these parts, about CASGEVY, we are excited about the programs that are going into late-stage trials, and also the programs that are in earlier development.
Got it. Yeah, it is a great intro, and you have had a couple data updates recently, including the data at AHA. So let us start there with CTX310. You showed some sHTG data with 63% mean triglyceride reduction at Day 30, alongside reductions in LDL and ApoB, despite this being a high-risk, all diabetic population. How should we contextualize that profile versus what we have seen with ApoC3 agents, and where could ANGPTL3 targeting offer a meaningful advantage?
Yeah, thank you for the question. I'll start, and then I'll hand it over to Naimish to talk to some of the nuances. This is a very exciting dataset. CTX310, for those who are new to the story, targets ANGPTL3, which actually acts on lipoprotein lipase and endothelial lipase, which then act on cholesterol. Long story short, we're putting a check on the brakes that are ANGPTL3, and by reducing ANGPTL3, you effectively unleash the lipoprotein lipases that then chew up the bad cholesterol, right? This is a one-time procedure where you're sitting in a chair for two and a half to three hours, one infusion, and then you're done for life. It's a very attractive proposition, generally, and this is a theme we've been following by one and done for lipid management and cardiovascular risk reduction.
As for the data we just presented at AHA, it was an incredible late breaker presentation, and Naimish, maybe you can talk through some of the data that we presented.
Yeah, absolutely. Just one more background item. The gene itself, ANGPTL3, was identified as a gene that's already naturally occurring mutations, originally in this Italian village where there's a high rate of loss of function mutations, ANGPTL3. The patients who have that tend to have very low LDL, very low triglycerides, and low cardiovascular risk. This has been seen in multiple other populations, sort of that relationship as well. All we're trying to do is recapitulate that mutation with our drug. Our initial data last year at AHA, published in the New England Journal, showed that with a single dose, we could not only produce potent reductions in LDL and triglycerides, but those were durable out to a year. Truly, a single dose can cause a lifetime, potentially, of reduction in lipids.
This is transformational for lipid reduction, because the biggest barrier to patients' control today is compliance with medicines. Our more recent AHA data was in severe hypertriglyceridemia. We had a mean reduction, as you mentioned, close to 65%, which is essentially on par with the ApoC3 olezarsen or the siRNA. Every company presents their data a little bit different, mean versus median, but in terms of the effect size, it's there. What we've also shown with that data is eight of 10 patients got below 500, which is the key metric for basically getting rid of the pancreatitis risk associated with triglycerides. The other differentiation points are lowering of atherogenic lipids, which is also very differentiated from the other mechanisms, as the only mechanism that does that.
Got it. Yeah, makes sense. These patients, they start with quite high baseline triglycerides relative to other studies. Beyond the mean percent reduction, what proportion of patients do you expect to achieve normal or near normal triglyceride levels?
Yeah. So basically, as I just mentioned, eight of 10 patients, even at Day 28, and we've seen responses deepen over time. Even early data, almost every patient we've treated, we've removed their pancreatitis risk, and that's really the first point that you're looking for treating these patients. The other thing is, these patients are at high risk for cardiovascular outcomes, and it's unclear if just targeting ApoC3 will do that, because the LDL seems to increase in some patients, where here, we saw a reduction in LDL, ApoC3, and non-HDL cholesterol, all key differentiation points and all associated with atherogenic risk.
Got it. That could potentially differentiate you versus the ApoC3 agents.
Absolutely. A couple of other things. We'll have more data on glucose control. Genetic studies suggest knocking down ANGPTL3 actually increases insulin resistance, or decreases insulin resistance, which is a positive, as well as hepatic fat that we don't have the data on yet, but we hope to report upon in the coming year.
Got it. There was the one patient who is a non-responder. Any color on that patient's baseline characteristics or what may have driven the lack of response?
Yeah. I mean, I guess for any drug, it's not unusual to see heterogeneity in response. There's nothing specific about that patient we've identified. I can also say that we've dosed, because we have three other cohorts going in this study, patients with just hypercholesterolemia, patients with familial hypercholesterolemia, and also patients with mixed dyslipidemia, and we've been actively enrolling all of those as well, and we've dosed many more patients. We haven't seen any other patients quite like that, so we think it's probably an unusual occurrence. I think the key is looking at the mean reduction, and it's on par with what we need to get.
Got it. Okay. Talk about liver fat, and whether that could be a differentiator versus ApoC3. You captured baseline hepatic fat fraction at approximately 20%. Did liver fat actually fall on CTX310, and do you have the MRI-PDFF data on that?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
